RU2000127036A - N-SUBSTITUTED AMINOTETRALINES AS LIGANDS FOR Y5 NEUROPEPTIDE Y5 RECEPTOR, USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS - Google Patents
N-SUBSTITUTED AMINOTETRALINES AS LIGANDS FOR Y5 NEUROPEPTIDE Y5 RECEPTOR, USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERSInfo
- Publication number
- RU2000127036A RU2000127036A RU2000127036/04A RU2000127036A RU2000127036A RU 2000127036 A RU2000127036 A RU 2000127036A RU 2000127036/04 A RU2000127036/04 A RU 2000127036/04A RU 2000127036 A RU2000127036 A RU 2000127036A RU 2000127036 A RU2000127036 A RU 2000127036A
- Authority
- RU
- Russia
- Prior art keywords
- halogen
- alkyl
- group
- substituted
- amino
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 8
- 208000008589 Obesity Diseases 0.000 title claims 2
- 235000020824 obesity Nutrition 0.000 title claims 2
- 102000020213 Neuropeptide Y5 receptor Human genes 0.000 title 1
- 108010046593 Neuropeptide Y5 receptor Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 claims 31
- 150000002367 halogens Chemical class 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000001424 substituent group Chemical group 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- -1 nitro, amino Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000001624 naphthyl group Chemical group 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000004450 alkenylene group Chemical group 0.000 claims 5
- 125000002541 furyl group Chemical group 0.000 claims 5
- 125000002883 imidazolyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000004419 alkynylene group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 4
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000005275 alkylenearyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010020565 Hyperaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010039911 Seizure Diseases 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 201000006233 congestive heart failure Diseases 0.000 claims 1
- 201000008286 diarrhea Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000006180 eating disease Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 230000001850 reproductive Effects 0.000 claims 1
- 230000001568 sexual Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
Images
Claims (22)
где R1 выбирают, независимо, из группы, состоящей из водорода; гидрокси; галогена; C1-8-алкокси; замещенного C1-8-алкокси, где заместитель представляет собой галоген; трифторалкила; С1-8-алкилтио и замещенного C1-8-алкилтио, где заместитель выбирают из галогена, трифторалкила и C1-8-алкокси; С3-8-циклоалкила; С3-8-циклоалкокси; нитро; амино; C1-6-алкиламино; C1-8-диалкиламино; С4-8-циклоалкиламино; циано; карбокси; C1-5-алкоксикарбонила; С1-5-алкилкарбонилокси; формила; карбамоила; фенила; замещенного фенила, где заместитель выбирают из галогена, гидроксила, нитро, амино и циано;
n = 0-2;
В2 выбирают из группы, состоящей из водорода; C1-5-алкила; замещенного С1-5-алкила, где заместителем является галоген;
Y представляет собой метилен;
m = 0-3;
R2 выбирают из группы, состоящей из водорода; гидрокси; C1-6-алкила; C1-6-алкенила; С3-7-циклоалкила; галогена; фенила; замещенного фенила, где заместитель выбирают среди галогена, С1-6-алкила, С1-6-алкокси, трифтор-C1-6-алкила, циано, нитро, амино, C1-6-алкиламино и C1-6-диалкиламино; нафтила; фенокси; замещенного фенокси, где заместитель выбирают из галогена, С1-6-алкила, C1-6-алкокси, трифтор-С1-6-алкила, циано и нитро; фенилтио и замещенного фенилтио, где заместитель выбирают из галогена, С1-6-алкила, нитро и амино; гетероарильной группы, такой как пиридил, пиримидил, фурил, тиенил и имидазолил; замещенного гетероарила, где заместитель выбирают из С1-6-алкила и галогена; и гетероциклоалкила;
B1 выбирают из группы, состоящей из водорода; С1-5-алкила; замещенного С1-5-алкила, где заместителем является галоген;
L выбирают из группы, состоящей из С1-8-алкилена; C2-10-алкенилена; С2-10-алкинилена; С1-4-алкиленциклоалкил-С1-4-алкилена; С2-4-алкениленциклоалкил-С2-4-алкенилена; С2-4-алкиниленциклоалкил-С2-4-алкинилена; C1-4-алкиленарил-С1-4-алкилена; и С2-4-алкениленарил-С2-4-алкенилена;
R3 выбирают среди C1-8-алкила; замещенного C1-8-алкила, где заместитель выбирают из алкокси и галогена; циклоалкила; замещенного циклоалкила, где заместитель выбирают из алкокси и галогена; фенила; замещенного фенила, где заместитель выбирают из C1-8-алкила, галогена, нитро, амино, алкиламино, алкилсульфонила, алкокси и циано; нафтила; замещенного нафтила, где заместитель выбирают из галогена, нитро, амино и циано; гетероарила, где гетероарильную группу выбирают из пиридила, пирими-дила, фурила, тиенила и имидазолила; и замещенного гетероарила, где заместитель выбирают из галогена, нитро, амино и циано;
и его энантиомеры, диастереомеры и фармацевтически приемлемые соли.1. The compound of formula 1
where R 1 choose, independently, from the group consisting of hydrogen; hydroxy; halogen; C 1-8 alkoxy; substituted C 1-8 -alkoxy, where the Deputy is a halogen; trifluoroalkyl; C 1-8 alkylthio and substituted C 1-8 alkylthio, where the substituent is selected from halogen, trifluoroalkyl and C 1-8 alkoxy; C 3-8 cycloalkyl; C 3-8 cycloalkoxy; nitro; amino; C 1-6 -alkylamino; C 1-8 dialkylamino; C 4-8 cycloalkylamino; cyano; carboxy; C 1-5 alkoxycarbonyl; C 1-5 alkylcarbonyloxy; formula; carbamoyl; phenyl; substituted phenyl, where the Deputy is chosen from halogen, hydroxyl, nitro, amino and cyano;
n = 0-2;
B 2 is selected from the group consisting of hydrogen; C 1-5 alkyl; substituted C 1-5 -alkyl, where the substituent is halogen;
Y is methylene;
m = 0-3;
R 2 is selected from the group consisting of hydrogen; hydroxy; C 1-6 alkyl; C 1-6 alkenyl; C 3-7 cycloalkyl; halogen; phenyl; substituted phenyl, where the Deputy is chosen among the halogen, C 1-6 -alkyl, C 1-6 -alkoxy, trifluoro-C 1-6 -alkyl, cyano, nitro, amino, C 1-6 -alkylamino and C 1-6 - dialkylamino; naphthyl; phenoxy; substituted phenoxy, wherein the substituent is selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, trifluoro C 1-6 alkyl, cyano and nitro; phenylthio and substituted phenylthio, where the substituent is selected from halogen, C 1-6 alkyl, nitro and amino; a heteroaryl group such as pyridyl, pyrimidyl, furyl, thienyl, and imidazolyl; substituted heteroaryl, where the Deputy is selected from C 1-6 -alkyl and halogen; and heterocycloalkyl;
B 1 is selected from the group consisting of hydrogen; C 1-5 alkyl; substituted C 1-5 -alkyl, where the substituent is halogen;
L is selected from the group consisting of C 1-8 alkylene; C 2-10 alkenylene; C 2-10 alkynylene; C 1-4 alkylenecycloalkyl C 1-4 alkylene; C 2-4 alkenylencycloalkyl C 2-4 alkenylene; C 2-4 alkynylenecycloalkyl C 2-4 alkynylene; C 1-4 alkylene aryl C 1-4 alkylene; and C 2-4 alkenenaryl-C 2-4 alkenylene;
R 3 is selected from among C 1-8 alkyl; substituted C 1-8 -alkyl, where the substituent is selected from alkoxy and halogen; cycloalkyl; substituted cycloalkyl, where the Deputy is chosen from alkoxy and halogen; phenyl; substituted phenyl, wherein the substituent is selected from C 1-8 alkyl, halogen, nitro, amino, alkylamino, alkylsulfonyl, alkoxy, and cyano; naphthyl; substituted naphthyl, wherein the substituent is selected from halogen, nitro, amino, and cyano; heteroaryl, where the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl, and imidazolyl; and substituted heteroaryl, wherein the substituent is selected from halogen, nitro, amino, and cyano;
and its enantiomers, diastereomers and pharmaceutically acceptable salts.
рац-[1α, 2α(транс)] -N-[[[[[1,2,3,4-тетрагидро-6-метокси-1-(фенилметил)-2-нафталинил] амино] метил] -4-циклогексил] метил] -2-нафталинсульфонамид;
рац-[1α, 2α(транс)] -N-[[[1,2,3,4-тетрагидро-6-метокси-1-(фенилметил)-2-нафталинил] амино] -5-пентил] -2-нафталинсуль-фонамид;
рац-[1α, 2α(транс)] -N-[[[[[1,2,3,4-тетрагидро-6-метокси-1-(3-пиридинилметил)-2-нафталинил] амино] метил] -4-циклогек-сил] метил] -2-нафталинсульфонамид;
рац-[1α, 2α(транс)] -N-[[[[[1,2,3,4-тетрагидро-6-фтор-1-(фенилметил)-2-нафталинил] амино] метил] -4-циклогексил] метил] -2-фторбензолсульфонамид;
рац-[1α, 2α(транс)] -N-[[[[[1,2,3,4-тетрагидро-6-фтор-1-фенил-2-нафталинил] амино] метил] -4-циклогексил] метил] -2-наф-талинсульфонамид;
рац-[1α, 2α(транс)] -N-[[[[[1,2,3,4-тетрагидро-6-метокси-1-(1-пропен-3-ил)-2-нафталинил] амино] метил] -4-циклогексил] -метил] бензолсульфонамид;
рац-[1α, 2α(транс)] -N-[[[[[1,2,3,4-тетрагидро-6-метокси-1-(3-гидроксипропил)-2-нафталинил] амино] метил] -4-циклогексил] метил] бензолсульфонамид и
рац-[1α, 2α(транс)] -N-[[[[[1,2,3,4-тетрагидро-6-метокси-1-(н-пропил)-2-нафталинил] амино] метил] -4-циклогексил] метил] -бензолсульфонамид.2. The compound according to claim 1, selected from the group that includes
rac- [1α, 2α (trans)] -N - [[[[[1,2,3,4-tetrahydro-6-methoxy-1- (phenylmethyl) -2-naphthalenyl] amino] methyl] -4-cyclohexyl ] methyl] -2-naphthalenesulfonamide;
rac- [1α, 2α (trans)] -N - [[[1,2,3,4-tetrahydro-6-methoxy-1- (phenylmethyl) -2-naphthalenyl] amino] -5-pentyl] -2- naphthalenesulfonamide;
rac- [1α, 2α (trans)] -N - [[[[[1,2,3,4-tetrahydro-6-methoxy-1- (3-pyridinylmethyl) -2-naphthalenyl] amino] methyl] -4 -cyclohexyl-sil] methyl] -2-naphthalenesulfonamide;
rac- [1α, 2α (trans)] -N - [[[[[1,2,3,4-tetrahydro-6-fluoro-1- (phenylmethyl) -2-naphthalenyl] amino] methyl] -4-cyclohexyl ] methyl] -2-fluorobenzenesulfonamide;
rac- [1α, 2α (trans)] -N - [[[[[1,2,3,4-tetrahydro-6-fluoro-1-phenyl-2-naphthalenyl] amino] methyl] -4-cyclohexyl] methyl ] -2-naf-talinsulfonamide;
rac- [1α, 2α (trans)] -N - [[[[[1,2,3,4-tetrahydro-6-methoxy-1- (1-propen-3-yl) -2-naphthalenyl] amino] methyl] -4-cyclohexyl] -methyl] benzenesulfonamide;
rac- [1α, 2α (trans)] -N - [[[[[1,2,3,4-tetrahydro-6-methoxy-1- (3-hydroxypropyl) -2-naphthalenyl] amino] methyl] -4 -cyclohexyl] methyl] benzenesulfonamide and
rac- [1α, 2α (trans)] -N - [[[[[1,2,3,4-tetrahydro-6-methoxy-1- (n-propyl) -2-naphthalenyl] amino] methyl] -4 -cyclohexyl] methyl] -benzenesulfonamide.
где R1 выбирают, независимо, из группы, состоящей из водорода; гидрокси; галогена; С1-8-алкокси; замещенного C1-8-алкокси, где заместитель представляет собой галоген; трифторалкила; C1-8-алкилтио и замещенного C1-8-алкилтио, где заместитель выбирают из галогена, такого как хлор, бром, фтор и иод, трифторалкила и C1-8-алкокси; С3-6-циклоалкила; С3-8-циклоалкокси; нитро; амино; C1-8-алкиламино; C4-8-диалкиламино; C1-5-циклоалкиламино; циано; карбокси; C1-5-алкоксикарбонила; C1-5-алкилкарбонилокси; формила; карбамоила; фенила; замещенного фенила, где заместитель выбирают из галогена, гидроксила, нитро, амино и циано;
n = 0-2;
В2 представляет собой водород;
Y представляет собой метилен;
m = 0-3;
R2 выбирают из группы, состоящей из водорода; гидрокси; С1-6-алкила; C1-6-алкенила; галогена; С3-7-циклоалкила; фенила; замещенного фенила, где заместитель выбирают из галогена, C1-6-алкила, С1-6-алкокси, трифтор-С1-6-алкила, циано, нитро, амино, C1-6-алкиламино и C1-6-диалкиламино; нафтила; фенокси; замененного фенокси, где заместитель выбирают из галогена, С1-6-алкила, С1-6-алкокси, трифтор-С1-6-алкила, циано и нитро; фенилтио и замещенного фенилтио, где заместитель выбирают из галогена, C1-6-алкила, нитро и амино; гетероарильной группы, такой как пиридил, пиримидил, фурил, тиенил и имидазолил; замещенного гетероарила, где заместитель выбирают из C1-6-алкила и галогена; и гетероциклоалкила;
В1 представляет собой водород;
L выбирают из группы, состоящей из С1-8-алкилена; С2-10-алкенилена; С2-10-алкинилена; С1-4-алкиленциклоалкил-С1-4-алкилена; С2-4-алкениленцикло-алкил-С2-4-алкенилена; С2-4-алкиниленциклоалкил-С2-4-алкинилена; C1-4-алкиленарил-C1-4-алкилена; и С2-4-алкениленарил-С2-4-алкенилена;
R3 выбирают из С1-8-алкила; замещенного C1-8-алкила, где заместитель выбирают из алкокси и галогена; циклоалкила; замещенного циклоалкила, где заместитель выбирают из алкокси и галогена; фенила; замещенного фенила, где заместитель выбирают из C1-8-алкила, галогена, нитро, амино, алкиламино, алкилсульфонила, алкокси и циано; нафтила; замещенного нафтила, где заместитель выбирают из галогена, нитро, амино и циано; гетероарила, где гетероарильную группу выбирают из пиридила, пиримидила, фурила, тиенила и имидазолила; и замещенного гетероарила, где заместитель выбирают из галогена, нитро, амино и циано;
и его энантиомеры, диастереомеры и фармацевтически приемлемые соли.4. The compound according to claim 1 of the formula
where R 1 choose, independently, from the group consisting of hydrogen; hydroxy; halogen; C 1-8 alkoxy; substituted C 1-8 -alkoxy, where the Deputy is a halogen; trifluoroalkyl; C 1-8 alkylthio and substituted C 1-8 alkylthio, where the substituent is selected from halogen, such as chlorine, bromine, fluorine and iodine, trifluoroalkyl and C 1-8 alkoxy; C 3-6 cycloalkyl; C 3-8 cycloalkoxy; nitro; amino; C 1-8 -alkylamino; C 4-8 dialkylamino; C 1-5 cycloalkylamino; cyano; carboxy; C 1-5 alkoxycarbonyl; C 1-5 alkylcarbonyloxy; formula; carbamoyl; phenyl; substituted phenyl, where the Deputy is chosen from halogen, hydroxyl, nitro, amino and cyano;
n = 0-2;
B 2 is hydrogen;
Y is methylene;
m = 0-3;
R 2 is selected from the group consisting of hydrogen; hydroxy; C 1-6 alkyl; C 1-6 alkenyl; halogen; C 3-7 cycloalkyl; phenyl; substituted phenyl, wherein the substituent is selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, trifluoro C 1-6 alkyl, cyano, nitro, amino, C 1-6 alkylamino and C 1-6 - dialkylamino; naphthyl; phenoxy; replaced by phenoxy, where the substituent is selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, trifluoro C 1-6 alkyl, cyano and nitro; phenylthio and substituted phenylthio, where the substituent is selected from halogen, C 1-6 alkyl, nitro and amino; a heteroaryl group such as pyridyl, pyrimidyl, furyl, thienyl, and imidazolyl; substituted heteroaryl, where the Deputy is selected from C 1-6 -alkyl and halogen; and heterocycloalkyl;
B 1 is hydrogen;
L is selected from the group consisting of C 1-8 alkylene; C 2-10 -alkenylene; C 2-10 alkynylene; C 1-4 alkylenecycloalkyl C 1-4 alkylene; C 2-4 alkenylencyclo-alkyl-C 2-4 alkenylene; C 2-4 alkynylenecycloalkyl C 2-4 alkynylene; C 1-4 alkylene aryl C 1-4 alkylene; and C 2-4 alkenenaryl-C 2-4 alkenylene;
R 3 is selected from C 1-8 -alkyl; substituted C 1-8 -alkyl, where the substituent is selected from alkoxy and halogen; cycloalkyl; substituted cycloalkyl, where the Deputy is chosen from alkoxy and halogen; phenyl; substituted phenyl, wherein the substituent is selected from C 1-8 alkyl, halogen, nitro, amino, alkylamino, alkylsulfonyl, alkoxy, and cyano; naphthyl; substituted naphthyl, wherein the substituent is selected from halogen, nitro, amino, and cyano; heteroaryl, wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl, and imidazolyl; and substituted heteroaryl, wherein the substituent is selected from halogen, nitro, amino, and cyano;
and its enantiomers, diastereomers and pharmaceutically acceptable salts.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8341598P | 1998-04-29 | 1998-04-29 | |
US60/083,415 | 1998-04-29 | ||
US09/290,651 US6140354A (en) | 1998-04-29 | 1999-04-12 | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders |
US09/290,651 | 1999-04-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000127036A true RU2000127036A (en) | 2002-08-27 |
RU2219167C2 RU2219167C2 (en) | 2003-12-20 |
Family
ID=26769275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000127036/04A RU2219167C2 (en) | 1998-04-29 | 1999-04-12 | N-substituted aminotetralines as ligands for receptor of y5 of neuropeptide y useful in treatment of obesity and other disorders |
Country Status (23)
Country | Link |
---|---|
US (1) | US6140354A (en) |
EP (1) | EP1076644B1 (en) |
JP (1) | JP2004503462A (en) |
CN (1) | CN1289475C (en) |
AT (1) | ATE269846T1 (en) |
AU (1) | AU759313B2 (en) |
BG (1) | BG64732B1 (en) |
BR (1) | BR9910583A (en) |
DE (1) | DE69918296T2 (en) |
DK (1) | DK1076644T3 (en) |
ES (1) | ES2223170T3 (en) |
HU (1) | HUP0102656A3 (en) |
ID (1) | ID26128A (en) |
IL (1) | IL139227A0 (en) |
NZ (1) | NZ507763A (en) |
PL (1) | PL194839B1 (en) |
PT (1) | PT1076644E (en) |
RO (1) | RO120542B1 (en) |
RU (1) | RU2219167C2 (en) |
TR (1) | TR200100137T2 (en) |
TW (1) | TW530043B (en) |
WO (1) | WO1999055667A1 (en) |
ZA (1) | ZA992951B (en) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE314371T1 (en) | 1998-11-10 | 2006-01-15 | Merck & Co Inc | SPIRO-INDOLE AS Y5 RECEPTOR ANTAGONISTS |
EP1177172A1 (en) * | 1999-05-05 | 2002-02-06 | Ortho-McNeil Pharmaceutical, Inc. | 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS |
US6841552B1 (en) | 1999-05-05 | 2005-01-11 | Ortho-Mcneil Pharmaceutical, Inc. | 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders |
MXPA02000927A (en) | 1999-07-28 | 2003-07-14 | Johnson & Johnson | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders. |
US20040254153A1 (en) * | 1999-11-08 | 2004-12-16 | Pfizer Inc | Compounds for the treatment of female sexual dysfunction |
KR100733752B1 (en) * | 1999-11-26 | 2007-06-29 | 시오노기세이야쿠가부시키가이샤 | Npyy5 antagonists |
GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
GB0011013D0 (en) * | 2000-05-09 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
US20030082647A1 (en) * | 2000-12-12 | 2003-05-01 | Reenan Robert A. | Transporter protein |
EP1399553A2 (en) | 2000-12-12 | 2004-03-24 | The University of Connecticut | Polynucleotides encoding cellular transporters and methods of use therof |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
GB0121941D0 (en) | 2001-09-11 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
DE60230818D1 (en) | 2001-09-24 | 2009-02-26 | Imp Innovations Ltd | PYY3-36 FOR REDUCING OR PREVENTING GREASE LUBRICITY |
CA2403307A1 (en) | 2001-10-23 | 2003-04-23 | Neurogen Corporation | Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives |
DE10157673A1 (en) * | 2001-11-24 | 2003-06-05 | Merck Patent Gmbh | Use of N- (indolecarbonyl) piperazine derivatives |
PL371471A1 (en) * | 2001-12-12 | 2005-06-13 | F.Hoffmann-La Roche Ag | Substituted cyclohexane derivatives |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
ATE533743T1 (en) * | 2002-05-17 | 2011-12-15 | Janssen Pharmaceutica Nv | UREA DERIVATIVES OF AMINOTETRALIN AS MODULATORS OF THE VANILLOID RECEPTOR VR1 |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
MXPA05009503A (en) | 2003-03-07 | 2005-10-18 | Schering Corp | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia. |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US20070099884A1 (en) * | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
WO2005000217A2 (en) * | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
ATE547404T1 (en) | 2003-09-22 | 2012-03-15 | Msd Kk | PIPERIDINE DERIVATIVES |
WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
WO2005114211A1 (en) * | 2004-05-21 | 2005-12-01 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor nyp5 (npy5) |
US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US20090156474A1 (en) | 2004-11-01 | 2009-06-18 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
WO2006108218A1 (en) * | 2005-04-15 | 2006-10-19 | Regenertech Pty Limited | Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
NZ562766A (en) | 2005-05-30 | 2011-03-31 | Banyu Pharma Co Ltd | Piperidine derivatives as histamine-H3 receptor antagonists |
GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
CA2618112A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
BRPI0616463A2 (en) | 2005-09-29 | 2011-06-21 | Merck & Co Inc | compound, pharmaceutical composition, and use of a compound |
JP2009512715A (en) | 2005-10-21 | 2009-03-26 | ノバルティス アクチエンゲゼルシャフト | Combination of renin inhibitor and anti-dyslipidemic agent and / or anti-obesity agent |
AU2006307046A1 (en) | 2005-10-27 | 2007-05-03 | Msd K.K. | Novel benzoxathiin derivative |
BRPI0618354B8 (en) | 2005-11-10 | 2021-05-25 | Banyu Pharma Co Ltd | compound and its use, pharmaceutical composition, preventive or medicine |
NZ572381A (en) * | 2006-04-28 | 2011-01-28 | Shionogi & Co | Amine derivative having npy y5 receptor antagonist activity |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
WO2008039327A2 (en) | 2006-09-22 | 2008-04-03 | Merck & Co., Inc. | Method of treatment using fatty acid synthesis inhibitors |
JPWO2008038692A1 (en) | 2006-09-28 | 2010-01-28 | 萬有製薬株式会社 | Diaryl ketimine derivatives |
TWI428346B (en) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CA3089569C (en) | 2007-06-04 | 2023-12-05 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
SA08290668B1 (en) * | 2007-10-25 | 2012-02-12 | شيونوجي آند كو.، ليمتد | Amine Derivatives having NPY Y5 receptor antagonistic activity and the uses thereof |
AU2007360979B2 (en) * | 2007-11-14 | 2014-04-10 | Amylin Pharmaceuticals, Llc | Methods for treating obesity and obesity related diseases and disorders |
AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
JP2011522828A (en) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders |
US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
MX2011004258A (en) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Novel cyclic benzimidazole derivatives useful anti-diabetic agents. |
KR101320245B1 (en) | 2008-10-30 | 2013-10-30 | 머크 샤프 앤드 돔 코포레이션 | Isonicotinamide orexin receptor antagonists |
JP5557845B2 (en) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Novel cyclic benzimidazole derivatives useful as antidiabetic agents |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US8227618B2 (en) | 2009-04-23 | 2012-07-24 | Shionogi & Co., Ltd. | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof |
EP2538784B1 (en) | 2010-02-25 | 2015-09-09 | Merck Sharp & Dohme Corp. | Benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
KR20150075120A (en) | 2011-02-25 | 2015-07-02 | 머크 샤프 앤드 돔 코포레이션 | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
AR088352A1 (en) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE |
US9227901B2 (en) | 2012-07-05 | 2016-01-05 | Abbvie Inc. | Process for preparing bicyclic amine derivatives |
RU2015106909A (en) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC TRICYCLIC COMPOUNDS |
KR20150118158A (en) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | Antidiabetic bicyclic compounds |
EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP6606491B2 (en) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | Ultra high purity agonist of guanylate cyclase C, method for producing and using the same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CA2959208C (en) | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
CN109952292A (en) | 2016-10-14 | 2019-06-28 | Tes制药有限责任公司 | Pantonine-carboxyl muconic acid semialdehyde removes the inhibitor of carboxylic acid |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
JP2022507805A (en) | 2018-11-20 | 2022-01-18 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α-Amino-β-carboxymuconic acid semialdehyde decarboxylase inhibitor |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
CA3189908A1 (en) | 2020-08-18 | 2022-02-24 | Stephane L. Bogen | Bicycloheptane pyrrolidine orexin receptor agonists |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3718317A1 (en) * | 1986-12-10 | 1988-06-16 | Bayer Ag | SUBSTITUTED BASIC 2-AMINOTETRALINE |
AU7692996A (en) * | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
WO1997019682A1 (en) * | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
-
1999
- 1999-04-12 ID IDW20002189A patent/ID26128A/en unknown
- 1999-04-12 EP EP99918500A patent/EP1076644B1/en not_active Expired - Lifetime
- 1999-04-12 US US09/290,651 patent/US6140354A/en not_active Expired - Lifetime
- 1999-04-12 WO PCT/US1999/007971 patent/WO1999055667A1/en active IP Right Grant
- 1999-04-12 DK DK99918500T patent/DK1076644T3/en active
- 1999-04-12 PL PL343771A patent/PL194839B1/en unknown
- 1999-04-12 TR TR2001/00137T patent/TR200100137T2/en unknown
- 1999-04-12 BR BR9910583-7A patent/BR9910583A/en not_active Application Discontinuation
- 1999-04-12 JP JP2000545828A patent/JP2004503462A/en active Pending
- 1999-04-12 NZ NZ507763A patent/NZ507763A/en unknown
- 1999-04-12 ES ES99918500T patent/ES2223170T3/en not_active Expired - Lifetime
- 1999-04-12 IL IL13922799A patent/IL139227A0/en not_active IP Right Cessation
- 1999-04-12 AT AT99918500T patent/ATE269846T1/en not_active IP Right Cessation
- 1999-04-12 DE DE69918296T patent/DE69918296T2/en not_active Expired - Fee Related
- 1999-04-12 RO ROA200001058A patent/RO120542B1/en unknown
- 1999-04-12 AU AU36400/99A patent/AU759313B2/en not_active Ceased
- 1999-04-12 CN CNB998053937A patent/CN1289475C/en not_active Expired - Fee Related
- 1999-04-12 HU HU0102656A patent/HUP0102656A3/en unknown
- 1999-04-12 PT PT99918500T patent/PT1076644E/en unknown
- 1999-04-12 RU RU2000127036/04A patent/RU2219167C2/en not_active IP Right Cessation
- 1999-04-26 ZA ZA9902951A patent/ZA992951B/en unknown
- 1999-05-26 TW TW088106980A patent/TW530043B/en not_active IP Right Cessation
-
2000
- 2000-10-23 BG BG104877A patent/BG64732B1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000127036A (en) | N-SUBSTITUTED AMINOTETRALINES AS LIGANDS FOR Y5 NEUROPEPTIDE Y5 RECEPTOR, USEFUL FOR THE TREATMENT OF OBESITY AND OTHER DISORDERS | |
RU2219167C2 (en) | N-substituted aminotetralines as ligands for receptor of y5 of neuropeptide y useful in treatment of obesity and other disorders | |
EP0729459B1 (en) | Phenyl-alkyl imidazoles as h3-receptor antagonists | |
EP0792264B1 (en) | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents | |
US20090005321A1 (en) | Phenylazetidinone Derivatives | |
US6020349A (en) | Constrained somatostatin agonists and antagonists | |
DE60013302T2 (en) | CYSTEIN PROTEASE INHIBITORS | |
AU668413B2 (en) | Diaryl piperazinoacetamide compounds as antimuscarinic agents | |
JP6077468B2 (en) | Asymmetric urea and its medical use | |
KR20070008620A (en) | Dipeptidyl peptidase inhibitors | |
EA200600327A1 (en) | BENZIMIDAZOLONE COMPOUNDS WITH AGONISTIC ACTIVITY AGAINST 5-NTRECEPTORS | |
US9427401B2 (en) | Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes | |
EP0437103A3 (en) | Substituted 5-(alkyl)carboxamide imidazoles | |
RU96112148A (en) | ANTAGONISTS OF ENDOTHELIN RECEPTORS | |
EP0912551A1 (en) | Somatostatin agonists and antagonists | |
RU2001120723A (en) | Imidazole derivatives and their medical use | |
KR920006316A (en) | Calcium absorption inhibitor | |
RU2003131970A (en) | 4- (Phenyl-piperidine-4-ylidene-methyl) -benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
US5190961A (en) | Thiourea derivatives and antimicrobial agent and antulcer agent containing the same | |
JP3436701B2 (en) | Treatment of pruritus | |
DK0542554T3 (en) | Substituted N-biphenylyllactams | |
WO1998058646A1 (en) | Use of somatostatin agonists and antagonists for treating diseases related to the eye | |
JP2002533339A (en) | Lipid-lowering compounds of S-oxide | |
DK0554107T3 (en) | Substituted triazoles as angiotensin II inhibitors | |
CS249149B2 (en) | Method of 2,5-disubstituted 4(3h)-pyrimidones' production |